United States Premenstrual Syndrome Treatment Market Report by Drug Type, Type, Distribution Channel, States and Company Analysis, 2025-2033

United States Premenstrual Syndrome Treatment Market Size and Forecast 2025-2033

The U.S. Premenstrual Syndrome Treatment Market is expected to grow from US$ 517.31 Million in 2024 to US$ 730.58 Million by 2033, growing at a CAGR of 3.91% from 2025 to 2033. Increased awareness of PMS, along with advancements in treatment options, will be the factors driving this growth owing to the greater need for effective healthcare solutions among symptomatic women.

United States Premenstrual Syndrome Treatment Market Outlook

Treatment approaches for the premenstrual syndrome are varied to alleviate the emotional and physical symptoms of PMS, which affect a large percentage of menstruating individuals. Symptoms can include mood swings, bloating, fatigue, and irritability and generally occur during the luteal phase of the menstrual cycle. Treatment options range from lifestyle modifications such as diet and exercise to pharmacological treatments like over-the-counter pain relievers and prescription medications, including antidepressants and hormonal therapies.

In the USA, PMS treatment has really gained significant momentum with greater awareness and understanding of the condition. Many people seek help because symptoms can be debilitating and affect daily life and relationships. Greater focus on women's health and wellness has resulted in more open discussions about PMS, reducing stigma and encouraging individuals to pursue effective treatments. Online platforms and health resources further facilitate this by allowing sharing of experiences and treatment strategies. Due to these factors, PMS treatment is now widely recognized and available, helping many find relief and improve the quality of their lives.

Growth Drivers in the United States Premenstrual Syndrome Treatment Market

Rising awareness of and diagnosis of PMS among women

In the U.S., increasing awareness pertaining to women's reproductive health has led to better diagnosis and treatment of premenstrual syndrome. This is mainly due to various campaigns taken by healthcare organizations, women's wellness brands, and public health agencies aimed at early identification and management of symptoms. More and more women are visiting physicians for mood swings, bloating, and cramps, which has led to increased adoption of pharmacological and non-pharmacological treatments. Awareness of the availability of effective treatment options spreads via social media and telehealth initiatives. Therefore, the concept of PMS has been incorporated into workplace wellness and health programs. This changing perception is encouraging more and more women to seek medical treatment, thereby driving demand for analgesics, antidepressants, and hormonal therapies. More than 90% of women experience premenstrual symptoms such as bloating, headaches, or mood swings during their reproductive years, according to the Office on Women's Health.

Expansion of Women’s Healthcare and Wellness Infrastructure

The continuous expansion of the women's healthcare infrastructure in the United States is a major driver for growth in the PMS treatment market. Increased investment in gynecology clinics, wellness centers, and hospital departments focused on hormonal health has facilitated better access to diagnosis and treatment. Healthcare providers increasingly integrate advanced treatment plans that include hormonal balancing therapies, antidepressants, and dietary supplements to treat symptoms of PMS holistically. In addition, growing access to telemedicine and online consultations has eased ways for women to avail professional care from the comfort of their homes, ensuring better convenience and compliance. Insurance coverage for women's health services has increased and is reducing financial burdens associated with regular management of PMS. February 2025: Opill® launched a multi-state college tour and expanded its WNBA partnership to improve reproductive health education and access. Through the "Level The Court" initiative with BWHI, it supported Black women's health equity. Events at universities and HBCUs promoted Opill® as an accessible, over-the-counter birth control option across restrictive states.

Growing demand for non-hormonal and natural therapies

Other key factors driving this market in the U.S. include an increasing preference for non-hormonal and natural therapies. Many are turning to herbal supplements, vitamins, and over-the-counter remedies instead of hormonal medications because of the associated risk of side effects or dependence. Nutraceutical options, which are increasingly gaining in popularity, relate to calcium, magnesium, and vitamin B6, while herbal solutions include chasteberry and evening primrose oil, among others. The other vital treatment orientations that have gained momentum as supplementary adjuncts involve yoga, diet management, and stress-reduction programs. The increasing number of consumer demands for plant-based and clean-label health products will encourage pharmaceutical and wellness firms to extend product offerings within this category. January 2025: The FDA granted approval to Journavx (suzetrigine), a first-in-class non-opioid oral analgesic intended for the treatment of adults with moderate to severe acute pain. Developed by Vertex Pharmaceuticals, it acts by targeting peripheral sodium channels and demonstrated superior pain relief in clinical studies. Journals created a new opioid-free choice that could potentially be used for pain-related symptoms in women’s health.

Challenge in the United States Premenstrual Syndrome Treatment Market

Lack of Standardized Diagnostic Criteria and Awareness Gaps

A couple of key challenges in the U.S. PMS treatment market include a lack of standardized diagnostic criteria and awareness gaps. The symptoms of PMS can be very heterogeneous among women; they often overlap with other disorders, such as anxiety or thyroid disorders, and are poorly diagnosed. Many women still self-diagnose the condition and use over-the-counter remedies without seeking medical advice. Moreover, different healthcare providers may use various methods of diagnosis, which leads to inconsistent results in the treatment outcome. This lack of uniformity in assessment and classification is a major obstacle to effective clinical management and limits the development of targeted therapies. Awareness remains particularly poor in under-resourced communities where access to gynecological care is limited. In the absence of broad-based education and standardization, many women continue to experience symptoms that are either untreated or mismanaged, thereby reducing the potential patient base for prescription treatments of PMS. Overcoming this challenge will require a coordinated public health response, better diagnostic tools, and increased awareness efforts for patients and healthcare professionals.

Side Effects and Limited Efficacy of Certain Drug Classes

Despite the gains made in therapy, concern over the side effects of drugs and the limited efficacy of some PMS medications poses major hurdles. Antidepressants, specifically SSRIs, which are among the most common medications prescribed for severe PMS and PMDD, produce such side effects as nausea, sleep disturbances, and sexual dysfunction. Similarly, hormonal therapies may promote weight gain, mood changes, or irregular bleeding, which makes long-term therapy unappealing. These often result in the abandonment of treatment or reluctance to embark on therapy. In addition, great variability in individual responses to medications makes the determination of universally effective measures difficult. Pharmaceutical companies are under pressure to develop safer, more targeted medicines with fewer side effects and greater tolerability. To surmount these obstacles, continuous clinical research and pharmaceutical innovation will be required in drug formulation, including extended-release and combination therapies, to enhance patient adherence and overall treatment outcomes.

United States Analgesics Premenstrual Syndrome Treatment Market

The U.S. analgesics PMS treatment market plays an important role in treating the physical symptoms of PMS, which include headaches, cramps, and muscle pain. The most common NSAIDs, such as ibuprofen and naproxen, are in higher demand due to their efficacy in reducing inflammation and fast action. Increased availability across pharmacies and online is improving access for women in search of convenience. Growth in this segment has been further encouraged by increased consumer preference for self-care and non-prescription treatments. Moreover, pharmaceutical companies are developing formulations with improved gastrointestinal tolerability and longer-lasting action. Product adoption has also gone up with increased awareness about the benefits of early pain management during menstrual cycles. As more women become interested in comfort and productivity while on cycle, demand for effective analgesic-based PMS solutions in the United States will continue to rise in the next years.

United States Antidepressants Premenstrual Syndrome Treatment Market

The U.S. antidepressants PMS treatment market is growing as more women seek relief from mood-related symptoms like irritability, depression, and anxiety that come with severe PMS and PMDD. SSRIs, like fluoxetine and sertraline, represent some of the most prescribed drugs because of their efficiency in normalizing mood swings and emotional instability. Greater acknowledgment of PMS as a medical condition and psychological management has motivated general practitioners to consider antidepressants as the first line of therapy. The introduction of low-dose presentations has significantly improved their acceptance among patients. Easy access to mental health support and its treatment, through telepsychiatry and online prescriptions, is also promoting the segment. However, managing potential side effects and patient compliance will be imperative for continued growth. The demand for antidepressant-based treatments for PMS is likely to strengthen with increased awareness of mental health in the United States.

United States Prescription Premenstrual Syndrome Treatment Market

The consistent growth of the U.S. prescription PMS treatment market is favored by the rise of medical consultations and the development of advanced drug therapy. Physicians increasingly treat both physical and emotional symptoms of PMS by prescribing hormonal contraceptives, antidepressants, and diuretics. Enhanced diagnostic practices with a greater understanding of hormonal imbalances have widened the horizon of prescription interventions. Besides, telehealth access has reduced the barriers of in-person clinic visits to access prescriptions and, thus, has also driven compliance with treatment. Manufacturing companies are heavily focusing on the development of combination drugs that can address multiple symptoms together, thus improving convenience and therapeutic outcome. Additional factors have been insurance coverage that strengthens the affordability of these women's health medications. Long-term symptom management seeks physician-recommended solutions, with more women considering it and the continued integration of mental and reproductive healthcare. Thus, the USPSTF market for prescription PMS treatments will see steady growth.

United States Premenstrual Syndrome Treatment Hospital Pharmacies Market

The U.S. hospital pharmacies PMS treatment market acts as a significant distribution channel for prescription and advanced therapeutic drugs. Hospitals also facilitate specialist consultations, which allow for better diagnosis and the administration of specific treatment for serious conditions of PMS and PMDD. Patients are treated with quality medications in the form of SSRIs, hormonal treatments, and nutritional supplements that are prescribed on the advice of practicing physicians through hospital-based pharmacies. Within hospitals, the growth of a women's healthcare department and gynecology clinics would further support this segment. Hospital pharmacies will have more varieties of prescription-grade medicines than retail outlets and can provide consistent supplies. A focus on integrated care-where gynecologists work in concert with psychiatrists and nutritionists-has improved treatment outcomes. With the further growth in hospital networks across the United States and increased trust by patients in institutional healthcare, the role of hospital pharmacies is expected to increase further in the United States PMS treatment landscape.

United States Premenstrual Syndrome Treatment Online Stores Market

The U.S. online stores PMS treatment market is increasing rapidly due to the influence of e-commerce and telehealth platforms. Convenience and privacy are increasingly driving women toward online pharmacies to purchase over-the-counter and prescription PMS medications. Home delivery services, subscription-based refills, and digital consultations have improved accessibility, especially for busy professionals. Online platforms also tend to be highly price competitive and offer a wider product range, which encompasses herbal supplements, pain relievers, and antidepressants. The integration of digital health solutions, such as symptom-tracking apps, has further enhanced user engagement and medication adherence. However, regulatory oversight and counterfeit product risks remain concerns. Notwithstanding, growing consumer trust in licensed online pharmacies and health-tech solutions drives strong growth in this channel. As digital healthcare adoption continues to rise, online platforms are fast becoming a major distribution hub for PMS treatments in the United States.

California Premenstrual Syndrome Treatment Market

The California market for PMS treatment is fast-evolving, with high awareness of healthcare, strong access to medical facilities, and its women's wellness culture. Cities like Los Angeles, San Diego, and San Francisco will have a high concentration of gynecology clinics and wellness centers that offer advanced PMS therapies. The diversity of the population and the openness to natural health solutions raise demand for herbal supplements among people and holistic care options. Furthermore, California's strong digital health infrastructure promotes telemedicine consultations, through which patients can receive timely diagnoses and prescriptions. Universities and healthcare institutes in the state also contribute to research studies on women's hormonal health, thus driving innovation in treatment options. Advanced healthcare access, patient awareness, and lifestyle-focused treatment approaches make California a leading regional market for PMS treatment in the United States.

New Jersey Premenstrual Syndrome Treatment Market

The New Jersey PMS treatment market is growing, considering the increasing awareness of women's health and the availability of specialized medical services within the state. Its proximity to key pharmaceutical and biotechnology centers has spurred innovation in the development and availability of advanced therapeutic modalities for PMS. The hospitals and clinics of New Jersey are increasingly offering hormonal therapies, antidepressant prescriptions, and nutritional counseling. Growing awareness among women about the effects of PMS on mental health and work productivity is encouraging them to seek professional help. The overall insurance coverage and healthcare infrastructure of the state will further support this growth. Besides that, leading retail and online pharmacies ensure easy accessibility to both prescription and over-the-counter PMS medications. With continued emphasis on women's wellness and preventive care, New Jersey's PMS treatment market will continue to see steady and sustainable growth.

Washington Premenstrual Syndrome Treatment Market

The educated population of Washington, along with the emphasis on preventive healthcare, has set up a healthy growth path for the PMS treatment market. The health providers in the state are showing increasing interest in personalized treatment that integrates medication, therapy, and management of lifestyle. With advanced medical institutions and research studies on women's health, innovative treatment solutions are being developed. In addition, greater utilization of telehealth platforms and e-pharmacies across Washington has ensured better access to PMS medications, especially in suburban and rural areas. The progressive state mindset toward holistic wellness also creates demand for natural and alternative therapies. Partnerships between health providers and digital health companies further improve engagement and adherence among patients. With increasing awareness of hormonal and mental health issues, Washington is becoming a leading regional market in the United States for complete PMS treatment options.

Market Segmentation

Drug Type

• Analgesics
• Antidepressants
• Oral Contraceptives and Ovarian Suppression Agents
• Others

Type

• Prescription
• Over-the-Counter

Distribution Channel

• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Stores

Top States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Company Analysis:

• AbbVie Inc.
• BASF SE
• Bayer AG
• Dr. Reddy’s Laboratories Ltd
• Eli Lilly and Company
• GlaxoSmithKline Plc.
• H. Lundbeck A/S
• Pfizer Inc.
• SHIONOGI & Co. Ltd.

Report Details: